Home » Newsletters » BioWorld Science

BioWorld Science

May 30, 2011

View Archived Issues

Sulfated hyaluronic acid shows preclinical promise to treat prostate cancer

Johnson & Johnson discloses new adenosine A2A receptor antagonists

Halozyme Therapeutics presents recombinant human proteins with collagenolytic effects

New glucocorticoid receptor modulators prepared

Vantia presents novel kallikrein-1 inhibitors

Allopurinol may improve outcomes in patients with ischemic stroke

Johnson & Johnson claims novel delta opioid receptor ligands

New lysophospholipid LPA1 receptor antagonists prepared at sanofi-aventis

Kaken Pharmaceutical obtains approval in Japan for additional doses and indication of Ebutol

InSite Vision reaches SPA agreement with FDA for phase III trial of AzaSite Plus and DexaSite

Peregrine Pharmaceuticals begins bavituximab combination trial in prostate cancer

Tigris Pharmaceuticals begins phase II trial of AFP-464 in ER-positive breast cancer

Eszopiclone effectively treats insomnia as add-on to escitalopram in GAD and to fluoxetine in MDD

TD-1211 safety and pharmacokinetics assessed in healthy volunteers and patients with OIC

Isconova begins phase I trial of its Matrix M adjuvant with seasonal influenza vaccine

Pharmasset begins phase IIa PSI-7977/daclatasvir study for hepatitis C genotypes 1, 2 and 3

MAP Pharmaceuticals submits NDA for Levadex to FDA

Epitomics signs agreement with Bayer Schering Pharma for antibody technology

EMA accepts for review Savient Pharmaceuticals' MAA for Krystexxa

Medicago to collaborate with U.S. army on Ebola vaccine

Mitsubishi Tanabe Pharma launches antiallergy agent bepotastine besilate in China and Indonesia

Sanofi and DNDi enter 3-year collaboration to research nine neglected tropical diseases

U.S. government requests proposal from Emergent BioSolutions for supply BioThrax anthrax vaccine

EMA and Health Canada recommend revaccination with Ixiaro vaccine due to batch recall

FDA approves Dificid for treatment of CDI-associated diarrhea

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...